HighTower Advisors
FATE icon

HighTower Advisors’s Fate Therapeutics FATE Stock Holding History

HighTower Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-300
Closed -$1K – 3262
2021
Q2 		$1K Buy
+300
New +$24.2K ﹤0.01% 3103

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HighTower Advisors's FATE Position: Q2 2026 in Review

HighTower Advisors reduced its Fate Therapeutics (FATE) stake by 5.3% in Q2 2026, selling an estimated $3.46K and leaving 33,454 shares worth $90.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3666.

HighTower Advisors first reported a position in FATE in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.19M in Q2 2021. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • HighTower Advisors held 33,454 shares of Fate Therapeutics worth $90.3K as of Q2 2026.
  • HighTower Advisors sold 1,868 Fate Therapeutics shares in Q2 2026, an estimated $3.46K.
  • Fate Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3666 holding.
  • HighTower Advisors first reported a position in Fate Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • HighTower Advisors's Fate Therapeutics position peaked at $1.19M in Q2 2021.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.